Biology of Renal Cell Carcinoma

Front Matter....Pages i-xii
Front Matter....Pages 1-1
Classification of Renal Cell Carcinoma Based on Morphologic and Cytogenetic Correlations....Pages 3-12
Molecular Cytogenetic Stratification of Renal Cell Tumors....Pages 13-25
Oncogenes in Renal Cell Carcinoma....Pages 26-32
Molecular Studies of the VHL Tumor Suppressor Gene in Renal Cell Carcinoma....Pages 33-39
The Cloning of Tumor Suppressor Genes from the Short Arm of Human Chromosome 3 that Play a Role in the Development of Renal Cell Carcinoma....Pages 40-55
Expression of the Wilms’ Tumor Supressor Gene (WT1) in Renal Cell Carcinoma....Pages 56-62
Front Matter....Pages 63-63
Alterations in Signal Transduction in T Cells from Cancer Patients....Pages 65-71
Impaired Signal Transduction in Tumor Infiltrating T Cells from Patients with Renal Cell Carcinoma....Pages 72-83
Recruitment of MHC-Restricted Cytotoxic T Lymphocytes Specific for Renal Cell Carcinoma to the Tumor In Situ ....Pages 84-93
T-Lymphocyte Response in Renal Cell Carcinoma....Pages 94-105
Adhesion Molecules in Renal Cell Carcinoma....Pages 106-118
Front Matter....Pages 119-119
Cellular and Molecular Considerations for the Treatment of Murine Renal Cancer....Pages 123-132
2-5A-Antisense: A Novel Approach to Cancer Therapy....Pages 133-148
Analysis of Immune Response Induced by Tumors Engineered to Secrete Cytokines....Pages 149-160
New Avenues of Cancer Treatment: Modulation of Host Antitumor Directed Immune Responses by IL-4 and IL-12 in Renal Cell Cancer....Pages 161-173
Interleukin 12: Biology and Preclinical Studies of a New Anti-Tumor Cytokine....Pages 177-188
Cytokine Therapy of Metastatic Renal Cell Carcinoma: The Cleveland Clinic Experience....Pages 189-203
The Use of Cytokines, Tumor Infiltrating Lymphocytes, and Gene Therapy in the Treatment of Advanced Renal Cell Carcinoma: The UCLA Experience....Pages 204-209
Inhalational Interleukin-2 in the Treatment of Pulmonary Metastases in Patients with Renal Cell Carcinoma....Pages 210-223
Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon (αIFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer....Pages 224-234
Front Matter....Pages 119-119
T Cell Therapy of Patients with Advanced Renal Cell Carcinoma....Pages 235-248
Adoptive Immunotherapy with Interleukin-2 and LAK Cells or Gene Modified TIL in Patients with Renal Cell Carcinoma: Clinical and Laboratory Data....Pages 249-253
Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250....Pages 257-267
Back Matter....Pages 269-275